- Home
- GMAB vs MKC Comparison
GMAB vs MKC Comparison
Compare GMAB & MKC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- MKC
- Stock Information
- Founded
- GMAB 1999
- MKC 1889
- Country
- GMAB Denmark
- MKC United States
- Employees
- GMAB N/A
- MKC N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- MKC Packaged Foods
- Sector
- GMAB Health Care
- MKC Consumer Staples
- Exchange
- GMAB Nasdaq
- MKC Nasdaq
- Market Cap
- GMAB 17.4B
- MKC 17.6B
- IPO Year
- GMAB N/A
- MKC N/A
- Fundamental
- Price
- GMAB $29.93
- MKC $66.92
- Analyst Decision
- GMAB Strong Buy
- MKC Buy
- Analyst Count
- GMAB 7
- MKC 9
- Target Price
- GMAB $41.17
- MKC $77.33
- AVG Volume (30 Days)
- GMAB 3.1M
- MKC 3.0M
- Earning Date
- GMAB 11-06-2025
- MKC 10-07-2025
- Dividend Yield
- GMAB N/A
- MKC 2.69%
- EPS Growth
- GMAB 77.72
- MKC N/A
- EPS
- GMAB 21.62
- MKC 2.88
- Revenue
- GMAB $3,646,881,232.00
- MKC $6,787,900,000.00
- Revenue This Year
- GMAB $24.25
- MKC $2.64
- Revenue Next Year
- GMAB $16.29
- MKC $6.07
- P/E Ratio
- GMAB $13.36
- MKC $23.21
- Revenue Growth
- GMAB 32.97
- MKC 1.64
- 52 Week Low
- GMAB $17.24
- MKC $63.66
- 52 Week High
- GMAB $33.65
- MKC $86.24
- Technical
- Relative Strength Index (RSI)
- GMAB 46.39
- MKC 48.90
- Support Level
- GMAB $29.57
- MKC $66.85
- Resistance Level
- GMAB $30.24
- MKC $68.94
- Average True Range (ATR)
- GMAB 0.67
- MKC 1.45
- MACD
- GMAB -0.58
- MKC 0.21
- Stochastic Oscillator
- GMAB 11.11
- MKC 56.20
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About MKC McCormick & Company Incorporated
In its 135-year history, McCormick has become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond consumers, McCormick's customer base includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers. And its reach is extensive, with nearly 40% of sales generated beyond its home turf to 150 countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and Cholula, among others.